Every year, nearly 22,000 women in Thailand are reported to be diagnosed with breast cancer, with over 8000 of these cases ending in death.
Agilent is committed to fight cancer. Join us as we launch the latest indication on PD-L1 IHC 22C3 pharmDx for Triple Negative Breast Cancer (TNBC).
Moderator
Panadda Yanapirat
Vice-President
Medicare Supply Ltd. Part.
An overview of the new TNBC indication approved for PD-L1 IHC 22C3 pharmDx in Thailand
Stefanie Scheer
Global Product Marketing
Agilent Technologies, Denmark
Guiding Immune Checkpoint Inhibitor Therapy in Thailand
Dr Kroonpong Iampenkhae, MD.
Main Consultant for Breast Pathology,
King Chulalongkorn Memorial Hospital
D72115